Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 8, 2008, Pages 1313-1318

  Buller, Harry ^a   Deitchman, D ^b   Prins, M ^c   Segers, A ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b BRISTOL MYERS SQUIBB   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Organizational Anthropology   (Netherlands)

Author keywords

Apixaban; Dose ranging; DVT; Human; Novel anticoagulant; Treatment

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; TINZAPARIN; WARFARIN;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RECURRENCE; SAFETY; TREATMENT OUTCOME; VENOUS THROMBOSIS; VITAMIN K;

EID: 47649098524     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03054.x     Document Type: Article

References (10)

1. Buller HR., Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-28S.
2. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S-33S.
3. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005; 3: 1843-53.
4. Yavin YY, Wolozinsky M, Cohen AT. New antithrombotics in the prevention of thromboembolic disease. Eur J Intern Med 2005; 16: 257-66.
5. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-75.
6. The Persist Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004; 2: 47-53.
7. The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702.
8. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AEM, Cariou R, Leeuwenkamp O, Lensing AWA, for the Matisse investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med 2004; 140: 867-73.
9. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus A, Gent M, Pillion G, Piovella F, Prins MH, Raskob G. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-104.
10. van Dongen CJ, van Den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; 4: CD001100.